# A First-in-human, 3-part Study of MRT-8102 in Healthy Participants and Participants at Cardiovascular Risk With Elevated CRP

> **NCT07119125** · PHASE1 · RECRUITING · sponsor: **Monte Rosa Therapeutics, Inc** · enrollment: 100 (estimated)

## Conditions studied

- Healthy Volunteers
- Elevated CRP

## Interventions

- **DRUG:** MRT-8102
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07119125
- **Lead sponsor:** Monte Rosa Therapeutics, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-27
- **Primary completion:** 2026-01
- **Final completion:** 2026-03
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2025-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07119125

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07119125, "A First-in-human, 3-part Study of MRT-8102 in Healthy Participants and Participants at Cardiovascular Risk With Elevated CRP". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07119125. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*